FORENSIC TOXICOLOGY - Bio Medical Forensics

Methadone Disposition in Human
Breastmilk and Plasma in the Immediate
Perinatal Period
Disposition of Buprenorphine and
Norbuprenorphine in Human Meconium
Disposition of Nicotine and Metabolites in
Human Meconium Following In Utero
Tobacco Exposure
MDMA, HMMA, MDA, and HMA Plasma
Pharmacokinetics in Humans Following
Controlled MDMA Administration
Comparison of Various Liquid
Chromatography–Mass Spectrometry
Technologies for the Analysis of Forensic
Toxicology Samples for Commonly
Encountered Drugs
Marilyn A. Huestis, PhD*, and Diaa M. Shakleya, PhD,
National Institute on Drug Abuse, 5500 Nathan Shock
Drive, Baltimore, MD 21224; Robin Choo, PhD,
University of Pittsburgh, Titusville, PA; Martha L. Velez,
MD, The Johns Hopkins University School of Medicine,
Department of Pediatrics, 4940 Eastern Avenue,
Baltimore, MD 21224; Cheryl Harrow, RNC, MS, The
Johns Hopkins Bayview Medical Center, 4940 Eastern
Avenue, Baltimore, MD 21224; Jennifer R. Schroeder,
PhD, Office of the Clinical Director, Intramural Research
Program, National Institute on Drug Abuse, National
Institutes of Health, 5500 Nathan Shock Drive, Baltimore,
MD 21224; and Lauren M. Jansson, MD, The Johns
Hopkins University School of Medicine, Department of
Pediatrics, 4940 Eastern Avenue, Baltimore, MD 21224
Sherri L. Kacinko, BS*, National Institute on Drug Abuse,
5500 Nathan Shock Drive, Baltimore, MD 21224; Hendree
E. Jones, PhD, Johns Hopkins University, Johns Hopkins
Bayview Medical Center, 4940 Eastern Avenue D-3-E,
Baltimore, MD 21224; Rolley E. Johnson, PharmD, Reckitt
Benckiser Pharmaceuticals, 10710 Midlothian Turnpike
Suite 430, Richmond, VA 23235; Robin E. Choo, PhD,
University of Pittsburgh - Titusville, 504 East Main Street,
BCS 127, Titusville, PA; and Diaa M. Shakleya, PhD, and
Marilyn A. Huestis, PhD, Chemistry & Drug Metabolism,
Intramural Research, National Institute on Drug Abuse,
National Institutes of Health, 5500 Nathan Shock Drive,
Baltimore, MD 21224
Teresa R. Gray, MS*, National Institute on Drug Abuse,
Chemistry and Drug Metabolism, 5500 Nathan Shock
Drive, Baltimore, MD 21224; Raquel Magri, MD, Hospital
Pereyra Rossell, Ramble O’Higgins 4707, Montevideo,
cp11400, URUGUAY; and Diaa M. Shakleya, PhD, W.
David Darwin, BS, and Marilyn A. Huestis, PhD, National
Institute on Drug Abuse, National Institutes of Health,
5500 Nathan Shock Drive, Baltimore, MD 21224
Erin A. Kolbrich, BS*, Robert S. Goodwin, DO, PhD,
David A. Gorelick, MD, PhD, Robert J. Hayes, PhD,
Elliott A. Stein, PhD, and Marilyn A. Huestis, PhD,
Chemistry & Drug Metabolism, Intramural Research,
National Institute on Drug Abuse, National Institutes of
Health, 5500 Nathan Shock Drive, Baltimore, MD 21224
H. Chip Walls, BS*, University of Miami, Department of
Pathology, Forensic Toxicology Laboratory, 12500 SW
152nd Street, Building B, Miami, FL 33177; Peter R. Stout,
PhD*, and Jeri D. Ropero-Miller, PhD*, RTI
International, 3040 Cornwallis Road, PO Box 12194,
Building 3, Room 116, Research Triangle Park, NC 27709;
John M. Hughes, PhD, Agilent Technologies, 6612 Owens
Drive, Pleasanton, CA 94588; and Michael Zumwalt, PhD,
Agilent Technologies, 9780 South Meridian Boulevard,
Englewood, CO 80112
Index 28
112
112
113
114
114